MDMA Testifies at Congressional Hearing on Competition

MDMA testified before the House Committee on Small Business this week to describe the anticompetitive problems associated with the supplier-funded GPO model and certain dominant firm conduct. Representing MDMA was Said Hilal, CEO of Applied Medical Resources Group. The purpose of the hearing was to examine the lack of oversight and enforcement by DOJ and FTC of anticompetitive practices across a broad spectrum of industries. Hilal accurately highlighted two critical competition issue in the medical device arena: the supplier-funded GPO model and anticompetitive practices of certain dominant firms. Both create an inability for small, innovative medical technology companies to compete in the hospital marketplace.